Efficacy and Safety of Kefir Whey Postbiotics

12 Weeks, Randomized, Double-blind, Placebo-controlled Trial on the Efficacy and Safety of Kefir Whey Postbiotics

Research staff conduct screening tests only on applicants who provide written consent and select research subjects who meet the selection criteria. Study subjects will visit for the first time within 4 weeks from the screening visit to reexamine the suitability of the study subject selection/exclusion criteria and then be enrolled in the human application test. The participants will be randomly assigned to the kefir lactic acid bacteria-derived whey post-biotics group and the placebo group for the first time. Complete the baseline evaluation by the date of visit. Afterwards, the participants will consume whey postbiotics derived from kefir lactic acid bacteria and a placebo product twice a day, 3g per time, for 12 weeks, and visit the institution a total of four times to perform a grip strength test, DXA. This survey will be conducted at Hanyang University Hospital. Research staff may conduct follow-up observations of study subjects as needed after final consumption of the kefir lactic acid bacteria-derived whey postbiotic group and placebo products or after early termination.

Study Overview

• Status: Enrolling by invitation
• Conditions: Sarcopenia
• Intervention / Treatment: Dietary supplement: Whey postbiotics derived from kefir lactic acid bacteria; Dietary supplement: Placebo powder

Detailed Description

Purpose: Kefir (alcoholic fermented dairy product made by fermenting cow's milk, goat's milk, or sheep's milk) to determine the effect of 12 weeks of human consumption of whey postbiotics derived from lactic acid bacteria in improving muscle strength and intestinal microbiome in elderly people compared with placebo intake.

• Primary objective: To evaluate the effectiveness of whey postbiotics derived from kefir lactic acid bacteria compared to placebo intake through the results of the grip strength test for both hands.
• Secondary objective: To evaluate the effectiveness and safety of whey postbiotics derived from kefir lactobacilli for muscle strength improvement as assessed by dual energy x-ray absorptiometry (DXA), adipokines, myokines, and cytokines compared with placebo intake. The investigators aim to analyze the differences in the intestinal microbiome compared to placebo intake through fecal collection and NGS (Next Generation Sequencing).

Experimental product: Kefir lactic acid bacteria-derived whey postbiotics (oral intake of 6g per day (3g twice per day))

Control product: Flavor 2.7%, Calcium carbonate 13.8%, Lactose 41.3%, Maltodextrin 10.3%, Sugar 31.23%, Carboxy methyl cellulose 0.67% (oral intake of 6g per day (3g twice per day))

Number of subjects: In this human application test, in order to calculate the number of study subjects, the investigators referred to previous studies and calculated the lean mass gain (kg) of 3.3 ± 1.5 kg (mean ± SD) after consuming whey postbiotics derived from kefir lactic acid bacteria for 12 weeks. In the placebo group, it was assumed to be 1.8 ± 1.6 kg.

The statistical hypothesis test of the evaluation variable is a two-sided test.

The significance level is 5%. ③ The test power is maintained at 90% and the type 2 error is set at 0.2. ④ The ratio between the test group and the control group is divided at 1:1.

The calculation of the number of subjects referred to existing research, and a T-test was performed using the G power program to use the mean of the statistical difference in muscle strength improvement between the two groups divided according to the intake of whey postbiotics derived from kefir lactic acid bacteria as the mean (test power) (1-β)=0.9, significance level (α)=0.05, effect size (ES)=0.97 (Cohen's d)). The total number of research subjects required for human application testing calculated through this is 48. Here, the investigators plan to recruit a total of 60 research subjects, assuming a dropout rate of 20%.

Study Design

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of
    • Hanyang University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Adult men and women aged 40 years or older at the time of screening test
• Adult men and women with a Charlson Comorbidity Index (CCI) score of 0 at the time of screening
• Adult men and women with skeletal muscle mass less than 110% of the standard as measured by BIA (bioelectrical impedence analysis) at the time of screening test

Exclusion Criteria:

• Those with significant hypersensitivity to melon gourd, whey, or lactic acid bacteria ingredients
• Those who participated in other human application tests, diet, or exercise programs within 3 months before the screening test
• Persons with clinically significant acute or chronic cardiovascular, diabetes, endocrine, immune, respiratory, hepatobiliary, renal and urinary, neuropsychiatric, or gastrointestinal diseases requiring treatment.
• Those who show the following results in blood or urine tests: AST, ALT > 1.5 times the upper limit of the reference range, Serum Creatinine > 1.4 mg/dL, Fasting blood sugar > 126mg/dL
• If there is 2+ or more proteinuria
• Persons taking medication for psychiatric illness (excluding cases of intermittent medication due to sleep disorders)
• Those who consumed pro- or prebiotics within 1 month before the screening test
• Those who have taken protein supplements regularly for more than 3 months within 6 months before the screening test
• Those who received other investigational drugs within 1 month before the screening test
• Those who received antibiotics within 2 months before the screening test
• Those who are currently controlling their diet for disease management purposes
• Those with a history of gastrointestinal resection (excluding the appendix)
• Those who are performing or plan to perform regular resistance exercise
• People with vegetarian beliefs
• People with food allergies or restricted foods
• Persons with a history of diagnosed gastrointestinal disease (ex. ulcerative colitis, Crohn's disease, gastroparesis, peptic ulcer disease, cancer, celiac disease, short bowel, and ileostomy)
• Those taking constipation or diarrhea medication
• Those who currently smoke
• Those whose BMI exceeds 30kg/m2 at the time of screening test
• Those who plan to control their weight within 6 months after screening
• Those who are likely to be uncooperative in this test or those who are determined by the researcher to be unable to proceed with the test

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Kefir Postbiotics Group; 30 healthy adult participants; Appearance and formulation: Yellow powder/capsule with unique flavor and no off-flavor; Period of use: 12 months; Storage method: Store at room temperature; Manufacturing method: The whey postbiotics derived from kefir lactic acid bacteria used in the test food are produced in the laboratory at Hanyang University, and additional ingredients are purchased from finished products. Laboratory collects the ingredients and delivers them to the manufacturer, Neo Natural, to manufacture them so that there are no differences in properties and formulations.	Dietary supplement: Whey postbiotics derived from kefir lactic acid bacteria; Kefir (alcoholic fermented dairy product made by fermenting cow, goat, or sheep milk) whey derived from lactic acid bacteria postbiotics
Placebo Comparator: Control Group; 30 healthy adult participants; Appearance and formulation: Yellow powder/capsule with unique flavor and no off-flavor; Period of use: 12 months; Storage method: Store at room temperature; Manufacturing method: The same product without whey postbiotics.	Dietary supplement: Placebo powder; A powder product including Flavor, Calcium carbonate, Lactose, Maltodextrin, Sugar, Carboxy methyl cellulose. This cannot be distinguished from the postbiotics by inspection.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Grip strength test for both hands	Handgrip strength should be measured using the JAMAR grip dynamometer (Jamar, Plus+ Digital Hand Dynamometer, Preferred, USA). While the research subject is sitting, the grip strength of both hands is measured three times each, and the average value is taken as the representative value. The unit of grip strength is kg.	1) Day 0, 2) end of 12 weeks
Dual energy xray absorptiometry	Dexa imaging measures the whole body, lean mass, body fat mass, bone mineral content, and height using Hanyang University Hospital's DXA (Discovery W DEXA) equipment after fasting for more than 8 hours. Measurements will be taken with the study subject standing upright, rotating both feet inward about 15 degrees, and placing both hands next to the waist. Here, the investigators will measure skeletal muscle mass (SMM, kg) by subtracting bone mineral content from lean body mass. And the SMM (kg) and the height (m) will be combined to report skeletal muscle mass index (SMMI) in kg/m^2 unit.	Time Frame: 1) Day 0, 2) end of 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Biomarkers from blood	All in ng/mL : 1) adipokines (leptin, adiponectin) 2) myokines (myostatin, irisin) 3) lipid analysis (TG, T-C, HDL-C, LDL-C) 4) cytokines (CRP, IL-2, IL-6, IL-1β, TNF-α, IGF-1)	Time Frame: 1) Day 0, 2) end of 12 weeks
Confirmation of intestinal microorganisms	Stool collection is collected directly by the research subject 1 day before (24 hours) before the start of consumption of whey postbiotics derived from kefir lactic acid bacteria and after the last intake, and stored at a frozen temperature (-20℃ or lower) until the first and third visits. do. Research staff collect stool samples, store them frozen (-70°C), and then perform next-generation sequencing (NGS analysis).	Time Frame: 1) Day 0, 2) end of 12 weeks

Collaborators and Investigators

• Sponsor: Hanyang University
• Collaborators: Hanyang University Seoul Hospital
• Investigators: Principal Investigator: Jun Yup Kim, MD,MS, Hanyang University Seoul Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 26, 2023
• Primary Completion (Estimated): April 30, 2024
• Study Completion (Estimated): July 31, 2024

Study Registration Dates

• First Submitted: December 20, 2023
• First Submitted That Met QC Criteria: January 19, 2024
• First Posted (Actual): January 30, 2024

Study Record Updates

• Last Update Posted (Actual): February 20, 2024
• Last Update Submitted That Met QC Criteria: February 15, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Neurologic Manifestations; Neuromuscular Manifestations; Pathological Conditions, Anatomical; Muscular Atrophy; Atrophy; Sarcopenia
• Other Study ID Numbers: HYUH 2023-07-059-009

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No